IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY

被引：0

作者：

Cramer, P.

Chanan-Khan, A. ^{[1
]}

Demirkan, F. ^{[2
]}

Fraser, G. ^{[3
]}

Santucci Silva, R. ^{[4
]}

Pylypenko, H. ^{[5
]}

Grosicki, S. ^{[6
]}

Janssens, A. ^{[7
]}

Pristupa, A. ^{[8
]}

Mayer, J. ^{[9
]}

Dilhuydy, M. S. ^{[10
]}

Loscertales, J. ^{[11
]}

Bartlett, N. L. ^{[12
]}

Avigdor, A. ^{[13
,14
]}

Rule, S. ^{[15
]}

Sun, S. ^{[16
]}

Mahler, M. ^{[16
]}

Salman, M. ^{[16
]}

Howes, A. ^{[17
]}

Hallek, M. ^{[18
,19
]}

机构：

[1] Mayo Clin, IL-52621 Jacksonville, FL USA

[2] Dokuz Eylul Univ, Juravinski Canc Ctr, IL-69978 Izmir, Turkey

[3] McMaster Univ, Hemomed Oncol & Hematol, Hamilton PL6 8DH, ON, Canada

[4] IEP SAO LUCAS, Dept Hematol, Sao Paulo, Brazil

[5] Cherkassy Reg Oncol Ctr, Fac Publ Hlth, Dept Canc Prevent, Cherkassy, Ukraine

[6] Silesian Med Univ, D-50931 Katowice, Poland

[7] Univ Ziekenhuizen Leuven, D-50931 Leuven, Belgium

[8] Reg Clin Hosp, Dept Internal Med Hematol & Oncol, Ryazan, Russia

[9] Univ Hosp Brno, Brno, Czech Republic

[10] Hop Haut Leveque, Hematol Dept, IIS IP, Pessac, France

[11] Hosp Univ La Princesa, Sch Med, Siteman Canc Ctr, Madrid, Spain

[12] Washington Univ, Div Hematol & Bone Marrow Transplantat, St Louis, MO USA

[13] Chaim Sheba Med Ctr, Sackler Sch Med, Tel Hashomer, Israel

[14] Tel Aviv Univ, Dept Haematol, Tel Aviv, Israel

[15] Derriford Hosp, Plymouth, Devon, England

[16] Janssen Res & Dev LLC, Raritan, NJ USA

[17] Janssen Res & Dev, Dept Internal Med 1, High Wycombe, Bucks, England

[18] Univ Cologne, Ctr Integrated Oncol, Cologne, Germany

[19] Univ Cologne, Cologne, Germany

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB218

引用

页码：55 / 56

页数：2

共 50 条

[41] A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
Shouse, Geoffrey
Chen, Lu
Siddiqi, Tanya
Muir, Alex
Brown, Jennifer
Spurgeon, Stephen
Danilov, Alexey
LEUKEMIA & LYMPHOMA, 2023, 64 : S105 - S106
[42] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Byrd, John C.
Hillmen, Peter
Ghia, Paolo
Kater, Arnon P.
Chanan-Khan, Asher
Furman, Richard R.
O'Brien, Susan
Yenerel, Mustafa Nuri
Illes, Arpad
Kay, Neil
Garcia-Marco, Jose A.
Mato, Anthony
Pinilla-Ibarz, Javier
Seymour, John F.
Lepretre, Stephane
Stilgenbauer, Stephan
Robak, Tadeusz
Rothbaum, Wayne
Izumi, Raquel
Hamdy, Ahmed
Patel, Priti
Higgins, Kara
Sohoni, Sophia
Jurczak, Wojciech
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
[43] A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Shouse, Geoffrey P.
Chen, Lu
Siddiqi, Tanya
Muir, Alex
Brown, Jennifer R.
Spurgeon, Stephen E.
Danilov, Alexey
BLOOD, 2023, 142
[44] Final 5-Year Updated Results From a Phase 3 Study (HELIOS) of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 17 - 19
[45] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 13 - 14
[46] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Coutre, Steven
Byrd, John C.
Hillmen, Peter
Barrientos, Jacqueline C.
Barr, Paul M.
Devereux, Stephen
Robak, Tadeusz
Kipps, Thomas J.
Schuh, Anna
Moreno, Carol
Furman, Richard R.
Burger, Jan
O'Dwyer, Michael
Ghia, Paolo
Valentino, Rudolph
Suzuki, Samuel
Ninomoto, Joi
James, Danelle F.
O'Brien, Susan M.
BLOOD, 2016, 128 (22)
[47] Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A feasible and active regimen.
Byrd, JC
Grever, MR
Davis, B
Lucas, MS
Park, K
Goodrich, A
Morrison, C
Murphy, T
Kunkel, L
Grillo-Lopez, A
Waselenko, JK
Flinn, IW
BLOOD, 1999, 94 (10) : 704A - 705A
[48] A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
William, Basem M.
Brillhart, Kaylee
Afable, Manuel
Bakalarz, Kristen
Cooper, Brenda
Lazarus, Hillard M.
Gerson, Stanton L.
Creger, Richard
Nagabhushanam, Kalyanam
Grote, James
Fu, Pingfu
Kunati, Sandeep
Yang, Shuming
Xu, Yan
Woost, Philip
Jacobberger, James
de Lima, Marcos
Caimi, Paolo
BLOOD, 2018, 132
[49] Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Kipps, Thomas J.
Fraser, Graeme
Coutre, Steven
Brown, Jennifer R.
Barrientos, Jacqueline C.
Barr, Paul M.
Byrd, John C.
O'Brien, Susan M.
Dilhuydy, Marie-Sarah
Devereux, Stephen
Jaeger, Ulrich
Moreno, Carol
Cramer, Paula
Stilgenbauer, Stephan
Chanan-Khan, Asher A.
Mahler, Michelle
Salman, Mariya
Cheng, Mei
Londhe, Anil
Ninomoto, Joi
Howes, Angela
James, Danelle
Hallek, Michael
CANCER RESEARCH, 2017, 77
[50] Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
Barr, Paul M.
Munir, Talha
Brown, Jennifer R.
O'Brien, Susan Mary
Barrientos, Jacqueline Claudia
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine Si Lun
Mulligan, Stephen P.
Jager, Ulrich
Kipps, Thomas J.
Moreno, Carol
Montillo, Marco
Burger, Jan Andreas
Byrd, John C.
Hillmen, Peter
Dai, Sandra
Szoke, Anita
Dean, James P.
Woyach, Jennifer Ann
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →